STOCK TITAN

OS Therapies grants director 300,000 stock options

The options vest monthly over 12 installments, conditional on the director serving on each applicable vesting date.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

OS Therapies Inc (OSTX) director Avril Suzette McKean-Dieser was granted options to purchase 300,000 common shares on October 22, 2026, at an exercise price of $1.25 per share. The options vest in 12 equal installments on monthly anniversaries, provided she is serving as a director on each applicable vesting date, and expire October 22, 2036. She held 5,000 common shares directly after the reported transaction.

Insider McKean-Dieser Avril Suzette
Role Director
Type Security Shares Price Value
Grant/Award Stock options (right to buy) F1 300,000 $0.00 $0.00
Holding Common Stock -- -- --
Holdings After Transaction: Stock options (right to buy) — 300,000 contracts (Direct); Common Stock — 5,000 shares (Direct)
Footnotes (1)
  1. F1. On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on each applicable vesting date.
Options granted 300,000 options to purchase common shares Granted October 22, 2026
Exercise price $1.25 per share Options granted October 22, 2026
Vesting installments 12 equal installments On monthly anniversaries, subject to continued service as a director on each applicable vesting date
Common shares held directly 5,000 shares Following the reported transaction
Option expiration October 22, 2036 Options granted October 22, 2026
stock option award agreement financial
"terms and conditions of a stock option award agreement"
A stock option award agreement is a legal document that gives a person the right to buy a company’s shares at a fixed price later, with clear rules about when those rights become usable, how long they last, and any conditions for exercising them. For investors it matters because these agreements can increase the total shares outstanding and affect company costs and incentives—like a coupon that can turn into new stock, changing ownership and future stock supply.
amended and restated 2023 incentive compensation plan financial
"issuer's amended and restated 2023 incentive compensation plan"
vest financial
"options vest in 12 equal installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OSTX options did director Avril Suzette McKean-Dieser receive?

Avril Suzette McKean-Dieser received options to purchase 300,000 OS Therapies common shares on October 22, 2026, at an exercise price of $1.25 per share. The options expire October 22, 2036.

How do Avril Suzette McKean-Dieser's OSTX options vest?

The options vest in 12 equal installments on each monthly anniversary of the grant date, provided Avril Suzette McKean-Dieser is serving as a director on each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McKean-Dieser Avril Suzette

(Last)(First)(Middle)
C/O OS THERAPIES INCORPORATED
115 PULLMAN CROSSING ROAD, SUITE 103

(Street)
GRASONVILLE MARYLAND 21638

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock5,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock options (right to buy)$1.2510/22/2026A300,000 (1)10/22/2036Common Stock300,000$0300,000D
Explanation of Responses:
1. On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on each applicable vesting date.
/s/ Avril McKean-Dieser10/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading